218 related articles for article (PubMed ID: 12610208)
1. Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Hedenfalk I; Ringner M; Ben-Dor A; Yakhini Z; Chen Y; Chebil G; Ach R; Loman N; Olsson H; Meltzer P; Borg A; Trent J
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2532-7. PubMed ID: 12610208
[TBL] [Abstract][Full Text] [Related]
2. A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.
Didraga MA; van Beers EH; Joosse SA; Brandwijk KI; Oldenburg RA; Wessels LF; Hogervorst FB; Ligtenberg MJ; Hoogerbrugge N; Verhoef S; Devilee P; Nederlof PM
Breast Cancer Res Treat; 2011 Nov; 130(2):425-36. PubMed ID: 21286804
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors.
Fernández-Ramires R; Gómez G; Muñoz-Repeto I; de Cecco L; Llort G; Cazorla A; Blanco I; Gariboldi M; Pierotti MA; Benítez J; Osorio A
Int J Cancer; 2011 Jun; 128(11):2635-44. PubMed ID: 20715112
[TBL] [Abstract][Full Text] [Related]
5. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
6. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
8. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
9. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
[TBL] [Abstract][Full Text] [Related]
10. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
Alvarez S; Diaz-Uriarte R; Osorio A; Barroso A; Melchor L; Paz MF; Honrado E; Rodríguez R; Urioste M; Valle L; Díez O; Cigudosa JC; Dopazo J; Esteller M; Benitez J
Clin Cancer Res; 2005 Feb; 11(3):1146-53. PubMed ID: 15709182
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
Melchor L; Honrado E; Huang J; Alvarez S; Naylor TL; García MJ; Osorio A; Blesa D; Stratton MR; Weber BL; Cigudosa JC; Rahman N; Nathanson KL; Benítez J
Clin Cancer Res; 2007 Dec; 13(24):7305-13. PubMed ID: 18094411
[TBL] [Abstract][Full Text] [Related]
12. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
[TBL] [Abstract][Full Text] [Related]
13. Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Alvarez C; Aravena A; Tapia T; Rozenblum E; Solís L; Corvalán A; Camus M; Alvarez M; Munroe D; Maass A; Carvallo P
BMC Cancer; 2016 Mar; 16():219. PubMed ID: 26979459
[TBL] [Abstract][Full Text] [Related]
14. The "portrait" of hereditary breast cancer.
Lacroix M; Leclercq G
Breast Cancer Res Treat; 2005 Feb; 89(3):297-304. PubMed ID: 15754129
[TBL] [Abstract][Full Text] [Related]
15. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
[TBL] [Abstract][Full Text] [Related]
16. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
[TBL] [Abstract][Full Text] [Related]
17. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
Antoniou AC; Pharoah PD; McMullan G; Day NE; Ponder BA; Easton D
Genet Epidemiol; 2001 Jul; 21(1):1-18. PubMed ID: 11443730
[TBL] [Abstract][Full Text] [Related]
18. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
19. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
